1-[6-(2-Carboxypyrrolidin-1-yl)-6-oxohexanoyl]pyrrolidine-2-carboxylic acid (BioDeep_00000183309)

   

human metabolite blood metabolite


代谢物信息卡片


1-[6-(2-Carboxypyrrolidin-1-yl)-6-oxohexanoyl]pyrrolidine-2-carboxylic acid

化学式: C16H24N2O6 (340.1634)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 100%

分子结构信息

SMILES: C1CC(N(C1)C(=O)CCCCC(=O)N2CCCC2C(=O)O)C(=O)O
InChI: InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)

描述信息

同义名列表

2 个代谢物同义名

1-[6-(2-Carboxypyrrolidin-1-yl)-6-oxohexanoyl]pyrrolidine-2-carboxylic acid; 1-[6-(2-Carboxypyrrolidin-1-yl)-6-oxohexanoyl]pyrrolidine-2-carboxylate



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • David J Millar, Winston L Hutchinson, Mark B Pepys. Immunoradiometric assay for human serum amyloid P component. Journal of immunological methods. 2011 Aug; 371(1-2):18-24. doi: 10.1016/j.jim.2011.06.010. [PMID: 21708157]
  • Simon E Kolstoe, Steve P Wood. Drug targets for amyloidosis. Biochemical Society transactions. 2010 Apr; 38(2):466-70. doi: 10.1042/bst0380466. [PMID: 20298204]
  • Simon E Kolstoe, Basil H Ridha, Vittorio Bellotti, Nan Wang, Carol V Robinson, Sebastian J Crutch, Geoffrey Keir, Riitta Kukkastenvehmas, J Ruth Gallimore, Winston L Hutchinson, Philip N Hawkins, Stephen P Wood, Martin N Rossor, Mark B Pepys. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proceedings of the National Academy of Sciences of the United States of America. 2009 May; 106(18):7619-23. doi: 10.1073/pnas.0902640106. [PMID: 19372378]
  • Gideon M Hirschfield. Amyloidosis: a clinico-pathophysiological synopsis. Seminars in cell & developmental biology. 2004 Feb; 15(1):39-44. doi: 10.1016/j.semcdb.2003.12.013. [PMID: 15036205]
  • A W Lemstra, P Eikelenboom, E W Meijer, W A van Gool. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease]. Nederlands tijdschrift voor geneeskunde. 2002 Sep; 146(37):1720-3. doi: NULL. [PMID: 12357871]
  • M B Pepys, J Herbert, W L Hutchinson, G A Tennent, H J Lachmann, J R Gallimore, L B Lovat, T Bartfai, A Alanine, C Hertel, T Hoffmann, R Jakob-Roetne, R D Norcross, J A Kemp, K Yamamura, M Suzuki, G W Taylor, S Murray, D Thompson, A Purvis, S Kolstoe, S P Wood, P N Hawkins. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002 May; 417(6886):254-9. doi: 10.1038/417254a. [PMID: 12015594]
  • Jeff Herbert, Winston L Hutchinson, Jackie Carr, Jane Ives, Roland Jakob-Roetne, Ken-Ichi Yamamura, Misao Suzuki, Mark B Pepys. Influenza virus infection is not affected by serum amyloid P component. Molecular medicine (Cambridge, Mass.). 2002 Jan; 8(1):9-15. doi: 10.1007/bf03401998. [PMID: 11984001]